Phoenix Bio

研究発表

研究発表

Mode of action analysis for mouse liver tumor formation by MGK-264 and human relevance

    Yano, J. Kawamoto, K. Shimotsuma, Y. Ogata, K. Matsunaga, K. Abe, J. Fukunaga, S. Osimitz, T. G. Lake, B. G. Asano, H.
    Regul Toxicol Pharmacol. 2025 Dec;163:105929. doi: 10.1016/j.yrtph.2025.105929.

    Species-specific gene expression manipulation in humanized livers of chimeric mice via siRNA-encapsulated lipid nanoparticle treatment

      Yamazaki, K. Kubara, K. Sugahara, G. Muto, H. Yamamoto, M. Mano, Y. Mitsuhashi, K. Yamasaki, C. Ishida, Y. Tateno, C. Suzuki, Y.
      Mol Ther Methods Clin Dev. 2025 Apr 14;33(2):101466. doi: 10.1016/j.omtm.2025.101466.

      Prediction of human pharmacokinetics of procymidone and its major phase I and II metabolites using a PBPK__ model with enterohepatic circulation

        Hirasawa, K. Adachi, T. Takeuchi, H. Kuroda, T. Abe, J. Nakajima, M.
        Toxicol Appl Pharmacol. 2025 Aug 19;504:117525. doi: 10.1016/j.taap.2025.117525.

        Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection

          Zhou, J. Kaiser, H. Rocha, E. Terrell, A. N. Corti, D. Purcell, L. A. Lempp, F. A. Puschnik, A. S.
          JHEP Rep. 2025 Mar 22;7(6):101400. doi: 10.1016/j.jhepr.2025.101400. eCollection

          An evaluation of the human relevance of the hepatocellular tumors observed in mice treated with synthetic fungicide, pyridachlometyl, based on mode of action

            Kawamoto, K.Shimotsuma, Y.Maeda, K. Matsunaga, K. Asano, H. Cohen, S. M. Yamada, T.
            Arch Toxicol. 2025 Jun 9. doi: 10.1007/s00204-025-04099-9.

            Quantitative Prediction of Drug-Drug Interactions Arising from CYP3A4 Induction using Chimeric Mice with Humanized Liver

              Nakayama, K. Negoro, T. Takubo, H. Hayashi, A. Taniguchi, T. Nomura, Y. Iwanaga, K.
              Xenobiotica. 2025 Jun 11:1-19. doi: 10.1080/00498254.2025.2518239.

              Clinical potential of SAG-524: A novel HBV RNA destabilizer with a unique mechanism of action

                Tanaka, Yasuhito
                Glob Health Med. 2025 Feb 28;7(1):64-66. doi: 10.35772/ghm.2024.01078.

                Application of humanized mice to toxicology studies: properties of chimeric mice with humanized liver (PXB-mice) for hepatotoxicity

                  Sultana, N. Izawa, T. Kamei, T. Fujiwara, S. Ito, Y. Takami, Y. Kuwamura, M.
                  Drug Metab Dispos. 2025 Feb;53(2):100025. doi: 10.1016/j.dmd.2024.100025.

                  Quantitative prediction of drug disposition for uridine diphosphate-glucuronosyltransferase substrates using humanized mice

                    Miyake, T. Fujita, Y. Hirabayashi, M. Komiyama, N. Morita, K. Tachibana, T. Terao, K.
                    Drug Metab Dispos. 2025 Feb 10;53(4):100050. doi: 10.1016/j.dmd.2025.100050.

                    Development of human growth hormone-treated chimeric mice with humanized livers for an evaluation model of drug-induced fatty liver disease

                      Morioka, S. Sanoh, S. Ishida, Y. Furukawa, S. Ogawa, Y.Kotake, Y. Tateno, C.
                      Arch Toxicol. 2025 Feb 21. doi: 10.1007/s00204-025-03986-5.

                      Investigation of Biotransformation Pathways in a Chimeric Mouse with a Humanized Liver

                        Karlsson, I. B. Ekdahl, A. Etchingham-Coll, H. Li, X. Q. Ericsson, C. Ahlqvist, M. Samuelsson, K.
                        Int J Mol Sci. 2025 Jan 28;26(3):1141. doi: 10.3390/ijms26031141

                        Endothelial lipase-binding peptides similar to netrin-1 inhibit hepatitis B virus infection

                          Ide, M. Tabata, N. Murai, K. Yonemura, Y. Wang, Y. Ishida, A. Shirasaki, T. Kaneko, S. Ito, S. Honda, M. Yanagawa, H.
                          FEBS Lett. 2025 Jan 25. doi: 10.1002/1873-3468.15101.

                          Induction of phospholipase A2 group 4C by HCV infection regulates lipid droplet formation

                            Ito, M. Liu, J. Fukasawa, M. Tsutsumi, K. Kanegae, Y. Setou, M. Kohara, M. Suzuki, T.
                            JHEP Rep. 2024 Sep 30;7(1):101225. doi: 10.1016/j.jhepr.2024.101225.

                            Hepatitis B virus genotypes A1 and A2 have distinct replication phenotypes due to polymorphisms in the HBx gene

                              Zhang, M. Mouzannar, K. Zhang, Z. Teraoka, Y. Piotrowski, J. Ishida, Y. Tateno-Mukaidani, C. Saito, T.Abe-Chayama, H. Chayama, K.Liang, T. J.
                              PLoS Pathog. 2025 Jan 9;21(1):e1012803. doi: 10.1371/journal.ppat.1012803.

                              Theoretical modeling of hepatitis C acute infection in liver-humanized mice support pre-clinical assessment of candidate viruses for controlled-human-infection studies

                                Shi, Z. Mhlanga, A. Ishida, Y. Josephson, A. Collier, N. T. Abe-Chayama, H. Tateno-Mukaidani, C. Cotler, S. J. Ozik, J. Major, M. Feld, J. J. Chayama, K. Dahari, H.
                                Sci Rep. 2024 Dec 30;14(1):31826. doi: 10.1038/s41598-024-83104-0.

                                Alteration of Gene Expression After Entecavir and Pegylated Interferon Therapy in HBV-Infected Chimeric Mouse Liver

                                  Bao, H. Murakami, S. Tsuge, M. Uchida, T. Uchikawa, S. Fujino, H. Ono, A. Murakami, E. Kawaoka, T. Miki, D. Hayes, C. N. Oka, S.
                                  Viruses. 2024 Nov 6;16(11):1743. doi: 10.3390/v16111743.

                                  An atlas of the human liver diurnal transcriptome and its perturbation by hepatitis C virus infection

                                    Mukherji, A. Jühling, F. Simanjuntak, Y. Crouchet, E. Del Zompo, F. Teraoka, Y. Haller, A. Baltzinger, P. Paritala, S. Rasha, F. Fujiwara, N. Gadenne, C. Slovic, N. Oudot, M. A. Durand, S. C.
                                    Nat Commun. 2024 Aug 29;15(1):7486. doi: 10.1038/s41467-024-51698-8.

                                    Plasma and urinary CP I and CP III concentrations in chimeric mice with human hepatocytes after rifampicin administration

                                      Shishido, Y. Yoshida, T. Oshida, K. Uchida, M.
                                      Pharmacol Res Perspect. 2024 Oct;12(5):e70017. doi: 10.1002/prp2.70017.

                                      Infectivity of Hepatitis B Virus Surface Antigen-Positive Plasma With Undetectable HBV-DNA: Can HBsAg Screening Be Discontinued in Egyptian Blood Donors?

                                        El Ekiaby, M. Tanaka, J. van Drimmelen, H. Allain, J. P. Lelie, N.
                                        J Viral Hepat. 2024 Aug 10. doi: 10.1111/jvh.13990.

                                        Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV/HDV infected humanized mice

                                          Duehren, S. Uchida, T. Tsuge, M. Hiraga, N. Uprichard, S. L. Etzion, O. Glenn, J. Koh, C. Heller, T. Cotler, S. J. Oka, S. Chayama, K. Dahari, H.
                                          Virus Res. 2024 Aug 26;349:199451. doi: 10.1016/j.virusres.2024.199451.